Trial Profile
A Randomized, Double-Blinded, Placebo-Controlled, Dose-Ranging Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli) in Healthy Female Subjects Aged 18 to 25 Years
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2024
Price :
$35
*
At a glance
- Drugs Human papillomavirus 16/18 vaccine recombinant bivalent Xiamen Innovax (Primary) ; Hepatitis B vaccine recombinant
- Indications Cervical cancer; Hepatitis B; Human papillomavirus infections
- Focus Pharmacodynamics
- 04 Jan 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
- 21 Feb 2014 Planned End Date changed from 1 Dec 2011 to 1 Dec 2017 as reported by ClinicalTrials.gov record.
- 21 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record.